NeuroOne Medical Technologies (OTCMKTS:NMTC) and Acutus Medical (NASDAQ:AFIB) Head to Head Survey – Defense World
Posted by admin on Jul 11th, 2022
Acutus Medical (NASDAQ:AFIB – Get Rating) and NeuroOne Medical Technologies (OTCMKTS:NMTC – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.
Analyst Recommendations
This is a summary of recent ratings and price targets for Acutus Medical and NeuroOne Medical Technologies, as provided by MarketBeat.
Acutus Medical currently has a consensus price target of $4.83, indicating a potential upside of 464.31%. NeuroOne Medical Technologies has a consensus price target of $2.63, indicating a potential upside of 162.50%. Given Acutus Medical’s higher possible upside, analysts plainly believe Acutus Medical is more favorable than NeuroOne Medical Technologies.
Insider and Institutional Ownership
63.0% of Acutus Medical shares are held by institutional investors. Comparatively, 11.2% of NeuroOne Medical Technologies shares are held by institutional investors. 24.3% of Acutus Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Acutus Medical has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Comparatively, NeuroOne Medical Technologies has a beta of -0.72, indicating that its stock price is 172% less volatile than the S&P 500.
Earnings & Valuation
This table compares Acutus Medical and NeuroOne Medical Technologies’ gross revenue, earnings per share and valuation.
NeuroOne Medical Technologies has lower revenue, but higher earnings than Acutus Medical. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Acutus Medical, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Acutus Medical and NeuroOne Medical Technologies’ net margins, return on equity and return on assets.
Summary
Acutus Medical beats NeuroOne Medical Technologies on 8 of the 13 factors compared between the two stocks.
About Acutus Medical (Get Rating)
Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. The company's product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.
About NeuroOne Medical Technologies (Get Rating)
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
Receive News & Ratings for Acutus Medical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Acutus Medical and related companies with MarketBeat.com’s FREE daily email newsletter.
Hiscox’s (HSX) Sector Perform Rating Reiterated at Royal Bank of Canada
Costco Wholesale Co. Forecasted to Post Q1 2023 Earnings of $3.03 Per Share (NASDAQ:COST)